Company news
We Bioperfectus today solemnly and sincerely declare that our products:COVID-19 Coronavirus Real Time PCR Kit &COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit STAY NO DROP IN SENSITIVITY & SPECIFICITY IN FACE OF 9 MAJOR VARIANTS OF SARS-COV-2.
Information about 9 Major SARS-CoV-2 Variants
|
Lineage |
First Detected |
Earliest Day |
Spike Protein Substitutions |
Attributes |
|
B.1.1.7 |
United Kingdom |
February 7, 2020 |
Δ69/70, Δ144, (E484K*), (S494P*), N501Y, A570D, D614G, P681H, T716I, S982A, D1118H (K1191N*) |
~50% increased transmission Likely increased severity based on hospitalizations and case fatality rates Minimal impact on neutralization by EUA monoclonal antibody treatments Minimal impact on neutralization by convalescent and post-vaccination sera |
|
B.1.351 |
South Africa |
May 11, 2020 |
D80A, D215G, Δ241/242/243, K417N, E484K, N501Y, D614G, A701V |
~50% increased transmission Reduction in neutralization by some, but not all EUA monoclonal antibody treatments Moderate reduction in neutralization by convalescent and post-vaccination sera |
|
P.1 |
Japan/ |
November 30, 2020 |
L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I |
Reduction in neutralization by some, but not all EUA monoclonal antibody treatments Reduced neutralization by convalescent and post-vaccination sera |
|
P.2 |
Brazil |
April 15, 2020 |
E484K, (F565L*), D614G, V1176F |
Potential reduction in neutralization by monoclonal antibody treatments Reduced neutralization by post-vaccination sera |
|
B.1.525 |
United Kingdom, Nigeria |
December 11, 2020 |
A67V, Δ69/70, Δ144, E484K, D614G, Q677H, F888L |
Potential reduction in neutralization by monoclonal antibody treatments Potential reduction in neutralization by convalescent and post-vaccination sera |
|
B.1.526 |
United States-(New York) |
November 23, 2020 |
(L5F*), T95I, D253G, (S477N*), (E484K*), D614G, (A701V*) |
Reduced neutralization by some, but not all EUA monoclonal antibody treatments Reduced neutralization by convalescent and post-vaccination sera |
|
B.1.427 |
United States-(California) |
March 15, 2020 |
L452R, D614G |
~20% increased transmissibility Significant reduction in neutralization by some, but not all, EUA monoclonal antibody treatments Moderate reduction in neutralization using convalescent and post-vaccination sera |
|
B.1.429 |
United States-(California) |
April 15, 2020 |
S13I, W152C,L452R, D614G |
~20% increased transmissibility Significant reduction in neutralization by some, but not all, EUA monoclonal antibody treatments Moderate reduction in neutralization using convalescent and post-vaccination sera |
|
B.1.617 |
India |
February 25, 2021 |
Under research |
Under research |
|
References: https://cov-lineages.org/lineages.html https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html |
||||
